Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
ARLINGTON, Va., April 12, 2016 -- FBR & Co. (Nasdaq:FBRC) (FBR), a leading investment bank serving the middle market, announced that Chris Meekins recently joined its equity research group and has initiated coverage on healthcare policy. Mr. Meekins is based in the Company’s Arlington, VA headquarters.
“Chris’s addition to our team brings a meaningful and unique policy perspective to our healthcare research that our clients want,” said FBR’s Director of Research and Senior Managing Director, David Hilal. “We have a great tradition of weaving together actionable investment ideas that are at the intersection of government policy and fundamental analysis. For the healthcare industry in particular, this differentiated approach provides our clients with tremendous value.”
Mr. Meekins came to FBR having spent four years as a senior health policy advisor and Chief of Staff for Congressman Andy Harris, M.D. During his tenure there, he helped pass reforms to the National Institutes of Health, increase funding for bio-defense, expand access to organs for transplantation, improve Medicare payments for physicians and increase transparency at the Food and Drug Administration. Before serving on the Hill, he worked in government affairs for the American Society of Anesthesiologists. Mr. Meekins holds a Bachelors of Arts from Gardner-Webb University.
FBR & Co. (Nasdaq:FBRC) provides investment banking, merger and acquisition advisory, institutional brokerage, and research services through its subsidiaries FBR Capital Markets & Co. and MLV & Co. FBR focuses capital and financial expertise on the following industry sectors: consumer; energy & natural resources; financial institutions; healthcare; industrials; insurance; real estate; and technology, media & telecom. FBR is headquartered in the Washington, D.C. metropolitan area with offices throughout the United States. For more information, please visit www.fbr.com.
Contacts Media: Shannon Hawkins at 703.469.1190 or [email protected] Investors: Linda E. Eddy at 703.312.9715 or [email protected]
